Estimating the Long-term Impact of a Prophylactic Human Papillomavirus 16/18 Vaccine on the Burden of Cervical Cancer in the UK

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Dec 6

PMID 17146475

Citations 27

Authors

M Kohli

N Ferko

A Martin

E L Franco

D Jenkins

S Gallivan

C Sherlaw-Johnson

M Drummond

Affiliations

Soon will be listed here.

Abstract

To predict the public health impact on cervical disease by introducing human papillomavirus (HPV) vaccination in the United Kingdom, we developed a mathematical model that can be used to reflect the impact of vaccination in different countries with existing screening programmes. Its use is discussed in the context of the United Kingdom. The model was calibrated with published data. The impact of vaccination on cervical cancer and deaths, precancerous lesions and screening outcomes were estimated for a vaccinated cohort of 12-year-old girls, among which it is estimated that there would be a reduction of 66% in the prevalence of high-grade precancerous lesions and a 76% reduction in cervical cancer deaths. Estimates for various other measures of the population effects of vaccination are also presented. We concluded that it is feasible to forecast the potential effects of HPV vaccination in the context of an existing national screening programme. Results suggest a sizable reduction in the incidence of cervical cancer and related deaths. Areas for future research include investigation of the beneficial effects of HPV vaccination on infection transmission and epidemic dynamics, as well as HPV-related neoplasms in other sites.

Citing Articles

Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.

Datta S, Pink J, Medley G, Petrou S, Staniszewska S, Underwood M BMC Infect Dis. 2019; 19(1):552.

PMID: 31234784 PMC: 6591963. DOI: 10.1186/s12879-019-4108-y.

Impact of HPV vaccination with Gardasil® in Switzerland.

Jacot-Guillarmod M, Pasquier J, Greub G, Bongiovanni M, Achtari C, Sahli R BMC Infect Dis. 2017; 17(1):790.

PMID: 29273004 PMC: 5741926. DOI: 10.1186/s12879-017-2867-x.

Cost-effectiveness of human papillomavirus vaccination in Germany.

Damm O, Horn J, Mikolajczyk R, Kretzschmar M, Kaufmann A, Delere Y Cost Eff Resour Alloc. 2017; 15:18.

PMID: 28878573 PMC: 5583986. DOI: 10.1186/s12962-017-0080-9.

Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.

Jackson C, Jit M, Sharples L, De Angelis D Med Decis Making. 2013; 35(2):148-61.

PMID: 23886677 PMC: 4847637. DOI: 10.1177/0272989X13493143.

Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.

Chesson H, Ekwueme D, Saraiya M, Dunne E, Markowitz L Vaccine. 2013; 31(37):3899-905.

PMID: 23820080 PMC: 6727206. DOI: 10.1016/j.vaccine.2013.06.050.

References

Munoz N, Bosch F, Castellsague X, Diaz M, de Sanjose S, Hammouda D . Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004; 111(2):278-85. DOI: 10.1002/ijc.20244. View

Bell S, Porter M, Kitchener H, Fraser C, Fisher P, Mann E . Psychological response to cervical screening. Prev Med. 1995; 24(6):610-6. DOI: 10.1006/pmed.1995.1096. View

Peto J, Gilham C, Deacon J, Taylor C, Evans C, BINNS W . Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004; 91(5):942-53. PMC: 2409880. DOI: 10.1038/sj.bjc.6602049. View

Peto J, Gilham C, Fletcher O, Matthews F . The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004; 364(9430):249-56. DOI: 10.1016/S0140-6736(04)16674-9. View

Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P . Human papillomavirus testing in primary cervical screening. Lancet. 1995; 345(8964):1533-6. DOI: 10.1016/s0140-6736(95)91086-7. View

Clifford G, Gallus S, Herrero R, Munoz N, Snijders P, Vaccarella S . Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366(9490):991-8. DOI: 10.1016/S0140-6736(05)67069-9. View

Sherlaw-Johnson C, Philips Z . An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer. 2004; 91(1):84-91. PMC: 2364742. DOI: 10.1038/sj.bjc.6601884. View

Clifford G, Smith J, Aguado T, Franceschi S . Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003; 89(1):101-5. PMC: 2394204. DOI: 10.1038/sj.bjc.6601024. View

Franco E, Villa L, Sobrinho J, PRADO J, Rousseau M, Desy M . Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999; 180(5):1415-23. DOI: 10.1086/315086. View

10.

Hopman E, Kenemans P, Helmerhorst T . Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. Obstet Gynecol Surv. 1998; 53(2):97-106. DOI: 10.1097/00006254-199802000-00021. View

11.

Karnon J, Peters J, Platt J, Chilcott J, Mcgoogan E, Brewer N . Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess. 2004; 8(20):iii, 1-78. DOI: 10.3310/hta8200. View

12.

Molano M, van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A . Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003; 158(5):486-94. DOI: 10.1093/aje/kwg171. View

13.

Wallace L, Bramley J, Ahmed S, Duff R, Hutchinson S, Carman W . Determinants of universal adolescent hepatitis B vaccine uptake. Arch Dis Child. 2004; 89(11):1041-2. PMC: 1719704. DOI: 10.1136/adc.2003.043687. View

14.

Canfell K, Barnabas R, Patnick J, Beral V . The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer. 2004; 91(3):530-6. PMC: 2409838. DOI: 10.1038/sj.bjc.6602002. View

15.

Mitchell M, Schottenfeld D, Tortolero-Luna G, Cantor S, Richards-Kortum R . Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998; 91(4):626-31. DOI: 10.1016/s0029-7844(98)00006-4. View

16.

Cantor S, Atkinson E, Cardenas-Turanzas M, Benedet J, Follen M, MacAulay C . Natural history of cervical intraepithelial neoplasia: a meta-analysis. Acta Cytol. 2005; 49(4):405-15. DOI: 10.1159/000326174. View

17.

de Rijke J, van der Putten H, Lutgens L, Voogd A, Kruitwagen R, Van Dijck J . Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of The Netherlands, 1986-1996. Eur J Cancer. 2002; 38(15):2041-7. DOI: 10.1016/s0959-8049(02)00315-5. View

18.

Jenkins D, Sherlaw-Johnson C, Gallivan S . Can papilloma virus testing be used to improve cervical cancer screening?. Int J Cancer. 1996; 65(6):768-73. DOI: 10.1002/(SICI)1097-0215(19960315)65:6<768::AID-IJC10>3.0.CO;2-0. View

19.

Harper D, Franco E, Wheeler C, Ferris D, Jenkins D, Schuind A . Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364(9447):1757-65. DOI: 10.1016/S0140-6736(04)17398-4. View

20.

Sherlaw-Johnson C, Gallivan S, Jenkins D, Jones M . Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling. J Clin Pathol. 1994; 47(5):430-5. PMC: 502020. DOI: 10.1136/jcp.47.5.430. View